iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Natco Pharma Ltd Peer Comparison

823.75
(-0.20%)
Mar 20, 2025|01:54:59 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

NATCO PHARMA LTD PEER COMPARISON

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,732.35

132.024,15,912.721,181.050.785,985.3398.33

Divis Laboratories Ltd

DIVISLAB

5,818.1

74.491,54,431.045940.512,297513.62

Cipla Ltd

CIPLA

1,499.15

261,21,021.11,438.150.874,134.87360.73

Torrent Pharmaceuticals Ltd

TORNTPHARM

3,191.3

59.231,08,045.554850.882,330222.38

Dr Reddys Laboratories Ltd

DRREDDY

1,172.1

18.8797,789.82849.40.684,997.8322.46

Natco Pharma: RELATED NEWS

Natco Pharma Gets USFDA Approval for Bosentan 32mg Tablets
12 Feb 2025|11:14 AM

The drug enhances the flow of blood through the lungs, allowing children with PAH to breathe and improve their ability to engage in physical activity.

Read More
Natco Pharma Sells Telangana Land for ₹115.57 Crore
1 Dec 2024|07:16 PM

The company was ensured that the sale of the land and building did not constitute part of its operational assets so that the sale will, in no way, impact the company's business operations

Read More
Natco Pharma Q2 Profit Surges 83%, Declares Interim Dividend
12 Nov 2024|10:26 PM

The revenue for the September quarter rose by 33% to ₹1,371 crore from ₹1,031 crore in the corresponding period last year.

Read More
Natco Pharma settles US patent case over generic Ozempic
7 Oct 2024|01:52 PM

According to data from the BSE index, the stock has achieved multibagger gains over the last two years, climbing 122.04%.

Read More
Cancer Patients Benefit as GST on Medications Slashed
10 Sep 2024|12:22 PM

The plan to reduce the GST on these drugs aims to significantly reduce the overall cost of cancer treatment.

Read More
Natco Pharma invests $8 million in US biotech firm eGenesis
4 Sep 2024|03:28 PM

Natco Pharma disclosed that its subsidiary will invest USD 8 million in eGenesis, acquiring a total of 40,629,761 shares.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.